Figure 3.

Consistent effect of nintedanib on reducing the rate of decline in FVC across subgroups by ILD diagnosis in the INBUILD trial. ⁴

Source: Wells et al. ⁴ Copyright (2020), with permission from Elsevier.

Treatment-by-subgroup-by-time interaction p = 0.41.

*Included rheumatoid arthritis-associated ILD, systemic sclerosis-associated ILD, mixed connective tissue disease-associated ILD, plus autoimmune disease-related ILDs in the “other fibrosing ILDs” category of the case report form.

^†Included sarcoidosis, exposure-related ILDs, and other terms in the “other fibrosing ILDs” category of the case report form.

FVC, forced vital capacity; ILD, interstitial lung disease.